Estimating the full public health value of vaccination (Q41922714)

14 October 2017

title

Estimating the full public health value of vaccination (English)

1 reference

14 October 2017

0 references

Katherine L O'Brien

5

0 references

Umesh Parashar

8

object named as

Umesh D Parashar

1 reference

14 October 2017

Mitra Saadatian-Elahi

9

object named as

Mitra Saadatian-Elahi

1 reference

14 October 2017

6

Valentina Picot

1 reference

14 October 2017

4

Kathleen Neuzil

1 reference

14 October 2017

1

Bradford D Gessner

1 reference

14 October 2017

David Kaslow

2

1 reference

14 October 2017

Jacques Louis

3

1 reference

14 October 2017

Tikki Pang

7

1 reference

14 October 2017

Christopher B Nelson

10

1 reference

14 October 2017

language of work or name

English

0 references

publication date

3 October 2017

1 reference

14 October 2017

1 reference

A global look at national Immunization Technical Advisory Groups

14 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Gastroenteritis hospitalizations in older children and adults in the United States before and after implementation of infant rotavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Beyond efficacy: The full public health impact of vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Comparing costs and outcomes across programmes of health care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

The broader economic impact of vaccination: reviewing and appraising the strength of evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Multicriteria decision analysis and core values for enhancing vaccine-related decision-making

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Use of vaccines as probes to define disease burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

First year experience of rotavirus immunisation programme in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Unacceptably high mortality related to measles epidemics in Niger, Nigeria, and Chad

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Estimates of measles case fatality ratios: a comprehensive review of community-based studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Costs of meningitis sequelae in children in Dakar, Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

A proposed framework for evaluating and comparing efficacy estimates in clinical trials of new rotavirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Effect of pentavalent rotavirus vaccine introduction on hospital admissions for diarrhoea and rotavirus in children in Rwanda: a time-series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Impact of Rotavirus Vaccination on Hospitalizations and Deaths From Childhood Gastroenteritis in Botswana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

The impoverished gut--a triple burden of diarrhoea, stunting and chronic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Influenza vaccination of pregnant women and protection of their infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Effectiveness of maternal influenza immunization in mothers and infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Stillbirth in developing countries: a review of causes, risk factors and prevention strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Effectiveness of maternal pertussis vaccination in England: an observational study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Maternal group B Streptococcus-related stillbirth: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

A role for Streptococcus pneumoniae in virus-associated pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Nasopharyngeal Microbiota, Host Transcriptome, and Disease Severity in Children with Respiratory Syncytial Virus Infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Respiratory Syncytial Virus Bronchiolitis: Enter the Microbiome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

How can health ministries present persuasive investment plans for women's, children's and adolescents' health?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

Cost-effectiveness thresholds: pros and cons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.048

10.1016/J.VACCINE.2017.09.048

7 January 2021

Identifiers

DOI

1 reference

14 October 2017

1 reference